fatty acid oxidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
==== Libya ==== The mummified remains of an infant were discovered during an expedition by archaeologist Fabrizio Mori to Libya during the winter of 1958–1959 in the natural cave structure of Uan Muhuggiag. After curious deposits and cave paintings were discovered on the surfaces of the cave, expedition leaders decided to excavate. Uncovered alongside fragmented animal bone tools was the mummified body of an infant, wrapped in animal skin and wearing a necklace made of ostrich egg shell beads. Professor Tongiorgi of the University of Pisa radiocarbon-dated the infant to between 5,000 and 8,000 years old. A long incision located on the right abdominal wall, and the absence of internal organs, indicated that the body had been eviscerated post-mortem, possibly in an effort to preserve the remains. A bundle of herbs found within the body cavity also supported this conclusion. Further research revealed that the child had been around 30 months old at the time of death, though sex could not be determined due to poor preservation of the sex organs.
=== Sheep === In sheep, ketosis, evidenced by hyperketonemia with beta-hydroxybutyrate in blood over 0.7 mmol/L, is referred to as pregnancy toxemia. This may develop in late pregnancy in ewes bearing multiple fetuses and is associated with the considerable metabolic demands of the pregnancy. In ruminants, because most glucose in the digestive tract is metabolized by rumen organisms, glucose must be supplied by gluconeogenesis. Pregnancy toxemia is most likely to occur in late pregnancy due to metabolic demand from rapid fetal growth and may be triggered by insufficient feed energy intake due to weather conditions, stress or other causes. Prompt recovery may occur with natural parturition, Caesarean section or induced abortion. Prevention through appropriate feeding and other management is more effective than treatment of advanced stages of pregnancy toxemia.
On 17 July 2007, following a four-year inquiry, the House of Commons Select Committee on Standards and Privileges published its sixth report. The Parliamentary Commissioner for Standards, in an addendum to the report, concluded that there was no evidence that Galloway gained any personal benefit from either the former Iraqi administration, or from the Oil-for-Food Programme, but admitted that some documents had been unavailable to him. However, the Committee concluded, in the main body of the report:
The daily intake of HMF may underlie high variations due to individual consumption-patterns. It has been estimated that the intakes range between 4 mg - 30 mg per person per day, while an intake of up to 350 mg can result from, e.g., beverages made from dried plums.
Sources: en.wikipedia.org
Knoxville's Greek community is perhaps best known for its restaurateurs, namely the Regas family, who operated a restaurant on North Gay Street from 1919 to 2010, and the Paskalis family, who founded the Gold Sun Cafe on Market Square around 1909. Notable members of Knoxville's Jewish community included jeweler Max Friedman and department store owner Max Arnstein. One of Knoxville's largest migrant groups consisted of rural people who moved to the city from the surrounding rural counties, often seeking wage-paying jobs in mills. Many of Knoxville's political and business leaders throughout the 20th century hailed from rural areas of Southern Appalachia.
The Association for Molecular Pathology (abbreviated AMP) is a professional association of individuals serving patients through molecular diagnostics testing. Founded in 1995, the Association has more than 3,100 members in over 50 countries. Molecular diagnostics is one of the fastest growing fields of health care. Molecular genetic testing provides patients and their doctors with accurate diagnosis of a broad range of cancers, infectious diseases, and inherited conditions. By identifying the exact molecular genetic alterations or biomarkers in a patient’s specimen, molecular genetic testing can identify treatment targets for personalized precision medicine that have improved outcomes for many patients. AMP is a volunteer-driven organization that concentrates on providing educational opportunities to practitioners and the broader medical community, advocating for the profession and the molecular professional, and advancing clinical care through the publication of evidence-based practice guidelines. AMP members work in academic and community medical centers, private and public health laboratories, government agencies, and the diagnostic manufacturing industry. Its membership includes pathologists, clinical laboratory scientists, technologists, trainees (who receive free membership while in training), clinicians and other health care personnel, government employees involved in regulatory oversight, and individuals in the in vitro diagnostics and pharmaceutical industries.
==== Flowering ==== Blooms occur when the day length becomes shorter than 12 hours (beginning in mid-October in some places), necessitating the use of shade cloth in urban environments with exposure to light pollution caused by HPS lighting. Both Siebert and hobbyist reports indicate that viable seeds can, on occasion, be produced under cultivation, following hand-pollination or hummingbird pollination.
=== Data modelling === Much of Aarons' work focuses on building an understanding of how the effects of drugs or toxic agents are managed in humans. In 2009 he co-authored a paper that aimed to explore an approach to the modelling of effects on people by drugs and toxic agents "based on the underlying physiology and pathology of the biological processes,...[ and to review]...the current status of pharmacodynamic and pharmacokinetic modelling, and outline a conceptual framework that may be helpful in advancing the field." A model was proposed that included the kinetics of the substance as a part of the process. To some extent, this was a challenge to the widely accepted dose/effect concept in pharmacology and toxicology at the time which assumed that the exposure/dose of a drug or a toxin is related to the effects on the patient, beneficial or toxic. The paper explained the purposes of data modelling as being to describe complex data, test hypotheses and make predictions, and noted when a drug interacts with a patient, there is a "chain of events at the molecular level, cellular level, organ/physiological system level, and whole-body level...[and ]... in principle, modelling may be performed at each of these levels." The effect on a patient could be therapeutic or possibly result in adverse outcomes. The authors concluded that including the systems biology model they discussed in the paper into conventional PKPD modelling would require further collaboration to make it robust but able to be clearly defined.
=== Anticoagulant medications === Anticoagulants may be started if the TIA is thought to be attributable to atrial fibrillation. Atrial fibrillation is an abnormal heart rhythm that may cause the formation of blood clots that can travel to the brain, resulting in TIAs or ischemic strokes. Atrial fibrillation increases stroke risk by five times, and is thought to cause 10-12% of all ischemic strokes in the US. Anticoagulant therapy can decrease the relative risk of ischemic stroke in those with atrial fibrillation by 67% Direct acting oral anticoagulants (DOACs), such as apixaban, are as effective as warfarin while also conferring a lower risk of bleeding. Generally, anticoagulants and antiplatelets are not used in combination, as they result in increased bleeding risk without a decrease in stroke risk. However, combined antiplatelet and anticoagulant therapy may be warranted if the patient has symptomatic coronary artery disease in addition to atrial fibrillation. Sometimes, myocardial infarction ("heart attack") may lead to the formation of a blood clot in one of the chambers of the heart. If this is thought to be the cause of the TIA, people may be temporarily treated with warfarin or another anticoagulant to decrease the risk of future stroke.
Sources: en.wikipedia.org
Biological molecular machines have been known and studied for decades given their vital role in sustaining life, and have served as inspiration for synthetically designed systems with similar useful functionality. The advent of conformational analysis, or the study of conformers to analyze complex chemical structures, in the 1950s gave rise to the idea of understanding and controlling relative motion within molecular components for further applications. This led to the design of "proto-molecular machines" featuring conformational changes such as cog-wheeling of the aromatic rings in triptycenes. By 1980, scientists could achieve desired conformations using external stimuli and utilize this for different applications. A major example is the design of a photoresponsive crown ether containing an azobenzene unit, which could switch between cis and trans isomers on exposure to light and hence tune the cation-binding properties of the ether. In his seminal 1959 lecture There's Plenty of Room at the Bottom, Richard Feynman alluded to the idea and applications of molecular devices designed artificially by manipulating matter at the atomic level. This was further substantiated by Eric Drexler during the 1970s, who developed ideas based on molecular nanotechnology such as nanoscale "assemblers", though their feasibility was disputed.
== Classification == In the third edition of the International Classification of Sleep Disorders (ICSD-3), obstructive sleep apnea is classified amongst the sleep-related breathing disorders and is divided in two categories, namely adult OSA and pediatric OSA. Obstructive sleep apnea is differentiated from central sleep apnea (CSA), which is characterized by episodes of reduction or cessation in breathing attributable to decreased effort, rather than upper airway obstruction. The respiratory effort must then be assessed in order to correctly classify the apnea as obstructive given the specificity of the diaphragmatic activity in this condition: the inspiratory effort is continued or increased through the entire episode of absent airflow. When hypopneas are present alongside apneas, the term obstructive sleep apnea-hypopnea is used. If it is associated with daytime sleepiness and other daytime symptoms, it is known as obstructive sleep apnea-hypopnea syndrome. To be categorized as obstructive, the hypopnea must meet one or more of the following symptoms: (1) snoring during the event, (2) increased oronasal flow flattening, or (3) thoraco-abdominal paradoxical respiration during the event. If none of them are present during the event, then it is categorized as central hypopnea.
== Research == Bimatoprost has been used to treat eyebrow hypotrichosis in a 60-year old female. The 0.03% solution was applied topically once a day for eight months and showed "increased hair growth and thickening of the eyebrow hairs". Bimatoprost and its endogenous analog prostaglandin F2α ethanolamide present the side-effect of being anti-adipogenic, and have been shown to be inducers of preadipocyte proliferation. These findings suggest bimatoprost is a possible therapy for obesity.
== History == Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell. In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016. In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.